Niagen Bioscience (NAGE) Receivables - Other (2013 - 2026)

Niagen Bioscience (NAGE) has reported Receivables - Other for 11 consecutive years, with $3.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Other rose 267.5% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $6.2 million (up 386.87% YoY), while the FY2025 annual figure was $756000.0, down 40.89% from the prior year.
• Receivables - Other improved to $3.4 million in Q1 2026 per NAGE's latest filing, from $1.3 million in the prior quarter.
• Across five years, Receivables - Other topped out at $3.8 million in Q4 2022 and bottomed at -$2.7 million in Q2 2023.
• Historically, Receivables - Other has averaged $904764.7 across 5 years, with a median of $1.3 million in 2025.
• Annual changes were most pronounced in 2022 — Receivables - Other surged 2802.31% — and 2023, when it sank 305.23%.
• Niagen Bioscience's Receivables - Other stood at $3.8 million in 2022, then slumped by 109.22% to -$348000.0 in 2023, then slumped by 84.48% to -$642000.0 in 2024, then surged by 296.57% to $1.3 million in 2025, then jumped by 170.36% to $3.4 million in 2026.
• Business Quant data shows NAGE's Receivables - Other at $3.4 million in Q1 2026, $1.3 million in Q4 2025, and -$1.2 million in Q3 2025.